BioNexus Gene Lab Corp. (BGLC)

Every figure this model derived for BGLC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 7,035 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 1,232,658 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 4,943,409 AssetsCurrent 2026-06-30
current liabilities 812,938 LiabilitiesCurrent 2026-06-30
equity 7,778,442 StockholdersEquity 2026-06-30
interest expense 4,561 InterestPaidNet 2026-06-30
ocf -846,565 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,126,581 Revenues 2026-06-30
sbc 794,770 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up BGLC on one particular measure came for.

RatioValue
cash operating margin-52.76
current ratio6.08
current ratio reported6.08
fcf margin-27.3
interest cover-560.89
operating margin-81.82
owner earnings margin-52.72
revenue growth-67.27
revenue growth per share-67.27
roic-30.63
rule of 40-149.09
sbc pct revenue25.42

What to be careful about

What this model itself distrusts about BGLC's figures. Written by the derivation as it ran, not added afterwards.